Endobarrier (EB) in Type 2 Diabetes/Prediabetes with Obstructive Sleep Apnea Study—Preliminary Results

Endobarrier (EB) in Type 2 Diabetes/Prediabetes with Obstructive Sleep Apnea Study—Preliminary Results

Aims: To assess the extent to which patients with type 2 diabetes or prediabetes, obesity (BMI 30-45kg/m²) and moderate OSA requiring continuous positive airway pressure ventilation (CPAP) are able to discontinue CPAP following EB-related weight loss (ISRCTN33788132). Methods: We assessed Apnoea Hyp...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Diabetes (New York, N.Y.) N.Y.), 2018-07, Vol.67 (Supplement_1)
Hauptverfasser: YADAGIRI, MAHENDER, KINNEY, FIONA Y., ASHMAN, NATALIE, LANG, MICHAEL H., FOGDEN, EDWARD, ANDERSON, MARK, BLEASDALE, JOHN, WALTON, CHRISTOPHER, GREENSTONE, MICHAEL A., RYDER, ROBERT E.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue Supplement_1
container_start_page
container_title Diabetes (New York, N.Y.)
container_volume 67
creator YADAGIRI, MAHENDER
KINNEY, FIONA Y.
ASHMAN, NATALIE
LANG, MICHAEL H.
FOGDEN, EDWARD
ANDERSON, MARK
BLEASDALE, JOHN
WALTON, CHRISTOPHER
GREENSTONE, MICHAEL A.
RYDER, ROBERT E.
description Aims: To assess the extent to which patients with type 2 diabetes or prediabetes, obesity (BMI 30-45kg/m²) and moderate OSA requiring continuous positive airway pressure ventilation (CPAP) are able to discontinue CPAP following EB-related weight loss (ISRCTN33788132). Methods: We assessed Apnoea Hypopnoea Index (AHI), weight and HbA1c before and following EB. The full study involves 18 patients receiving EB for up to 1 year with 1 year follow-up. Results: We report here the 1st 11 patients {9/11 (82%) female, 9/11 (82%) type 2 diabetes, 2/11 (18%) prediabetes, mean ± SD age 52.6 ± 9.7 years} to reach at least 3 months EB treatment. In 3 months, weight fell by 6.9 ± 3.3kg from 103.7 ± 14.8 to 96.8 ± 14.8kg (p
doi_str_mv 10.2337/db18-2071-P
format Article
fullrecord <record><control><sourceid>crossref</sourceid><recordid>TN_cdi_crossref_primary_10_2337_db18_2071_P</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_2337_db18_2071_P</sourcerecordid><originalsourceid>FETCH-crossref_primary_10_2337_db18_2071_P3</originalsourceid><addsrcrecordid>eNqVjztOw0AURUcIJEygYgOvBKEh85EYXPIxosNKUtCNxvGLMshxrPfGIHcsghWyEmwpG0C3uLe4pzhCXGp1a6x187rS99Iop2V5JDKd21xa496PRaaUNlK73J2KM-YPpdTdmExsi7beV4EoIsFV8XgNsYXV0CEYeI6hwoQ8Lwnrw4avmLbwVnGifp3iJ8KyQezgoWsxwDL19fD7_TMCTdzFNtAAC-S-SXwuTjahYbw49EzcvBSrp1e5pj0z4cZ3FHcj4LXyk4yfZPwk40v7v_cfb_1SiA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Endobarrier (EB) in Type 2 Diabetes/Prediabetes with Obstructive Sleep Apnea Study—Preliminary Results</title><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>YADAGIRI, MAHENDER ; KINNEY, FIONA Y. ; ASHMAN, NATALIE ; LANG, MICHAEL H. ; FOGDEN, EDWARD ; ANDERSON, MARK ; BLEASDALE, JOHN ; WALTON, CHRISTOPHER ; GREENSTONE, MICHAEL A. ; RYDER, ROBERT E.</creator><creatorcontrib>YADAGIRI, MAHENDER ; KINNEY, FIONA Y. ; ASHMAN, NATALIE ; LANG, MICHAEL H. ; FOGDEN, EDWARD ; ANDERSON, MARK ; BLEASDALE, JOHN ; WALTON, CHRISTOPHER ; GREENSTONE, MICHAEL A. ; RYDER, ROBERT E.</creatorcontrib><description>Aims: To assess the extent to which patients with type 2 diabetes or prediabetes, obesity (BMI 30-45kg/m²) and moderate OSA requiring continuous positive airway pressure ventilation (CPAP) are able to discontinue CPAP following EB-related weight loss (ISRCTN33788132). Methods: We assessed Apnoea Hypopnoea Index (AHI), weight and HbA1c before and following EB. The full study involves 18 patients receiving EB for up to 1 year with 1 year follow-up. Results: We report here the 1st 11 patients {9/11 (82%) female, 9/11 (82%) type 2 diabetes, 2/11 (18%) prediabetes, mean ± SD age 52.6 ± 9.7 years} to reach at least 3 months EB treatment. In 3 months, weight fell by 6.9 ± 3.3kg from 103.7 ± 14.8 to 96.8 ± 14.8kg (p&lt;0.001), mean BMI by 2.5 ± 1.3kg/m² from 37.1 ± 3.6 to 34.6 ± 3.7kg/m² (p&lt;0.001), mean HbA1c by 0.9±1.0% from 8.0±3.8 to 7.1±3.7% (p=0.025). OSA improved (Figure). Prior to EB, all 11 patients had AHI in moderate sleep apnoea range (15-29.9 events/hour). Following EB, the AHI of 7/11(64%) patients fell below the moderate sleep apnoea threshold of 15 events/hour, such that they no longer required CPAP. Of the remaining 4 patients, 1 came off CPAP at 6 months. Conclusion: These preliminary results are encouraging in that EB has already allowed 8/11(73%) patients to discontinue CPAP, in addition to glycaemic and weight benefits. Discontinuing CPAP is beneficial to health services but especially to patients.</description><identifier>ISSN: 0012-1797</identifier><identifier>EISSN: 1939-327X</identifier><identifier>DOI: 10.2337/db18-2071-P</identifier><language>eng</language><ispartof>Diabetes (New York, N.Y.), 2018-07, Vol.67 (Supplement_1)</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>YADAGIRI, MAHENDER</creatorcontrib><creatorcontrib>KINNEY, FIONA Y.</creatorcontrib><creatorcontrib>ASHMAN, NATALIE</creatorcontrib><creatorcontrib>LANG, MICHAEL H.</creatorcontrib><creatorcontrib>FOGDEN, EDWARD</creatorcontrib><creatorcontrib>ANDERSON, MARK</creatorcontrib><creatorcontrib>BLEASDALE, JOHN</creatorcontrib><creatorcontrib>WALTON, CHRISTOPHER</creatorcontrib><creatorcontrib>GREENSTONE, MICHAEL A.</creatorcontrib><creatorcontrib>RYDER, ROBERT E.</creatorcontrib><title>Endobarrier (EB) in Type 2 Diabetes/Prediabetes with Obstructive Sleep Apnea Study—Preliminary Results</title><title>Diabetes (New York, N.Y.)</title><description>Aims: To assess the extent to which patients with type 2 diabetes or prediabetes, obesity (BMI 30-45kg/m²) and moderate OSA requiring continuous positive airway pressure ventilation (CPAP) are able to discontinue CPAP following EB-related weight loss (ISRCTN33788132). Methods: We assessed Apnoea Hypopnoea Index (AHI), weight and HbA1c before and following EB. The full study involves 18 patients receiving EB for up to 1 year with 1 year follow-up. Results: We report here the 1st 11 patients {9/11 (82%) female, 9/11 (82%) type 2 diabetes, 2/11 (18%) prediabetes, mean ± SD age 52.6 ± 9.7 years} to reach at least 3 months EB treatment. In 3 months, weight fell by 6.9 ± 3.3kg from 103.7 ± 14.8 to 96.8 ± 14.8kg (p&lt;0.001), mean BMI by 2.5 ± 1.3kg/m² from 37.1 ± 3.6 to 34.6 ± 3.7kg/m² (p&lt;0.001), mean HbA1c by 0.9±1.0% from 8.0±3.8 to 7.1±3.7% (p=0.025). OSA improved (Figure). Prior to EB, all 11 patients had AHI in moderate sleep apnoea range (15-29.9 events/hour). Following EB, the AHI of 7/11(64%) patients fell below the moderate sleep apnoea threshold of 15 events/hour, such that they no longer required CPAP. Of the remaining 4 patients, 1 came off CPAP at 6 months. Conclusion: These preliminary results are encouraging in that EB has already allowed 8/11(73%) patients to discontinue CPAP, in addition to glycaemic and weight benefits. Discontinuing CPAP is beneficial to health services but especially to patients.</description><issn>0012-1797</issn><issn>1939-327X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNqVjztOw0AURUcIJEygYgOvBKEh85EYXPIxosNKUtCNxvGLMshxrPfGIHcsghWyEmwpG0C3uLe4pzhCXGp1a6x187rS99Iop2V5JDKd21xa496PRaaUNlK73J2KM-YPpdTdmExsi7beV4EoIsFV8XgNsYXV0CEYeI6hwoQ8Lwnrw4avmLbwVnGifp3iJ8KyQezgoWsxwDL19fD7_TMCTdzFNtAAC-S-SXwuTjahYbw49EzcvBSrp1e5pj0z4cZ3FHcj4LXyk4yfZPwk40v7v_cfb_1SiA</recordid><startdate>20180701</startdate><enddate>20180701</enddate><creator>YADAGIRI, MAHENDER</creator><creator>KINNEY, FIONA Y.</creator><creator>ASHMAN, NATALIE</creator><creator>LANG, MICHAEL H.</creator><creator>FOGDEN, EDWARD</creator><creator>ANDERSON, MARK</creator><creator>BLEASDALE, JOHN</creator><creator>WALTON, CHRISTOPHER</creator><creator>GREENSTONE, MICHAEL A.</creator><creator>RYDER, ROBERT E.</creator><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20180701</creationdate><title>Endobarrier (EB) in Type 2 Diabetes/Prediabetes with Obstructive Sleep Apnea Study—Preliminary Results</title><author>YADAGIRI, MAHENDER ; KINNEY, FIONA Y. ; ASHMAN, NATALIE ; LANG, MICHAEL H. ; FOGDEN, EDWARD ; ANDERSON, MARK ; BLEASDALE, JOHN ; WALTON, CHRISTOPHER ; GREENSTONE, MICHAEL A. ; RYDER, ROBERT E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-crossref_primary_10_2337_db18_2071_P3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>YADAGIRI, MAHENDER</creatorcontrib><creatorcontrib>KINNEY, FIONA Y.</creatorcontrib><creatorcontrib>ASHMAN, NATALIE</creatorcontrib><creatorcontrib>LANG, MICHAEL H.</creatorcontrib><creatorcontrib>FOGDEN, EDWARD</creatorcontrib><creatorcontrib>ANDERSON, MARK</creatorcontrib><creatorcontrib>BLEASDALE, JOHN</creatorcontrib><creatorcontrib>WALTON, CHRISTOPHER</creatorcontrib><creatorcontrib>GREENSTONE, MICHAEL A.</creatorcontrib><creatorcontrib>RYDER, ROBERT E.</creatorcontrib><collection>CrossRef</collection><jtitle>Diabetes (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>YADAGIRI, MAHENDER</au><au>KINNEY, FIONA Y.</au><au>ASHMAN, NATALIE</au><au>LANG, MICHAEL H.</au><au>FOGDEN, EDWARD</au><au>ANDERSON, MARK</au><au>BLEASDALE, JOHN</au><au>WALTON, CHRISTOPHER</au><au>GREENSTONE, MICHAEL A.</au><au>RYDER, ROBERT E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Endobarrier (EB) in Type 2 Diabetes/Prediabetes with Obstructive Sleep Apnea Study—Preliminary Results</atitle><jtitle>Diabetes (New York, N.Y.)</jtitle><date>2018-07-01</date><risdate>2018</risdate><volume>67</volume><issue>Supplement_1</issue><issn>0012-1797</issn><eissn>1939-327X</eissn><abstract>Aims: To assess the extent to which patients with type 2 diabetes or prediabetes, obesity (BMI 30-45kg/m²) and moderate OSA requiring continuous positive airway pressure ventilation (CPAP) are able to discontinue CPAP following EB-related weight loss (ISRCTN33788132). Methods: We assessed Apnoea Hypopnoea Index (AHI), weight and HbA1c before and following EB. The full study involves 18 patients receiving EB for up to 1 year with 1 year follow-up. Results: We report here the 1st 11 patients {9/11 (82%) female, 9/11 (82%) type 2 diabetes, 2/11 (18%) prediabetes, mean ± SD age 52.6 ± 9.7 years} to reach at least 3 months EB treatment. In 3 months, weight fell by 6.9 ± 3.3kg from 103.7 ± 14.8 to 96.8 ± 14.8kg (p&lt;0.001), mean BMI by 2.5 ± 1.3kg/m² from 37.1 ± 3.6 to 34.6 ± 3.7kg/m² (p&lt;0.001), mean HbA1c by 0.9±1.0% from 8.0±3.8 to 7.1±3.7% (p=0.025). OSA improved (Figure). Prior to EB, all 11 patients had AHI in moderate sleep apnoea range (15-29.9 events/hour). Following EB, the AHI of 7/11(64%) patients fell below the moderate sleep apnoea threshold of 15 events/hour, such that they no longer required CPAP. Of the remaining 4 patients, 1 came off CPAP at 6 months. Conclusion: These preliminary results are encouraging in that EB has already allowed 8/11(73%) patients to discontinue CPAP, in addition to glycaemic and weight benefits. Discontinuing CPAP is beneficial to health services but especially to patients.</abstract><doi>10.2337/db18-2071-P</doi></addata></record>
fulltext fulltext
identifier ISSN: 0012-1797
ispartof Diabetes (New York, N.Y.), 2018-07, Vol.67 (Supplement_1)
issn 0012-1797
1939-327X
language eng
recordid cdi_crossref_primary_10_2337_db18_2071_P
source EZB-FREE-00999 freely available EZB journals; PubMed Central
title Endobarrier (EB) in Type 2 Diabetes/Prediabetes with Obstructive Sleep Apnea Study—Preliminary Results
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T09%3A19%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-crossref&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Endobarrier%20(EB)%20in%20Type%202%20Diabetes/Prediabetes%20with%20Obstructive%20Sleep%20Apnea%20Study%E2%80%94Preliminary%20Results&rft.jtitle=Diabetes%20(New%20York,%20N.Y.)&rft.au=YADAGIRI,%20MAHENDER&rft.date=2018-07-01&rft.volume=67&rft.issue=Supplement_1&rft.issn=0012-1797&rft.eissn=1939-327X&rft_id=info:doi/10.2337/db18-2071-P&rft_dat=%3Ccrossref%3E10_2337_db18_2071_P%3C/crossref%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true